Allergan Inc



) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.1%. By the end of trading, Allergan Inc fell $1.47 (-1.8%) to $79.69 on heavy volume. Throughout the day, 3.2 million shares of Allergan Inc exchanged hands as compared to its average daily volume of 2.1 million shares. The stock ranged in price between $79.62-$81.30 after having opened the day at $81.24 as compared to the previous trading day's close of $81.16. Other company's within the Drugs industry that declined today were:

Poniard Pharmaceuticals Inc



), down 25.4%,

Bionovo Inc



), down 15.7%,

Geron Corporation



), down 10.7%, and

YM Biosciences Inc



), down 9.4%.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan Inc has a market cap of $25.13 billion and is part of the

health care

sector. The company has a P/E ratio of 27.7, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 18.2% year to date as of the close of trading on Monday.

TheStreet Ratings rates Allergan as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front,

Adeona Pharmaceuticals Inc



), up 19.1%,

ImmuCell Corporation



), up 16%,

Complete Genomics Inc



), up 14.2%, and

Cormedix Inc



), up 14%, were all gainers within the drugs industry with

Amgen Inc



) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech